148 related articles for article (PubMed ID: 35078225)
21. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
22. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
Kiely P; Busby AD; Nikiphorou E; Sullivan K; Walsh DA; Creamer P; Dixey J; Young A
BMJ Open; 2019 May; 9(5):e028466. PubMed ID: 31061059
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
Emery P; Fleischmann RM; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel B; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
[TBL] [Abstract][Full Text] [Related]
24. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
25. Liver Fibrosis in Rheumatoid Arthritis Patients Treated with Methotrexate.
Hilal G; Akasbi N; Boudouaya H; Salma K; Harzy T
Curr Rheumatol Rev; 2020; 16(4):293-297. PubMed ID: 32189595
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
28. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
[TBL] [Abstract][Full Text] [Related]
29. Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis.
Widdifield J; Abrahamowicz M; Paterson JM; Huang A; Thorne JC; Pope JE; Kuriya B; Beauchamp ME; Bernatsky S
J Rheumatol; 2019 May; 46(5):467-474. PubMed ID: 30504508
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.
Tesser J; Kafka S; DeHoratius RJ; Xu S; Hsia EC; Turkiewicz A
Arthritis Res Ther; 2019 Aug; 21(1):190. PubMed ID: 31429794
[TBL] [Abstract][Full Text] [Related]
31. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
32. Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis.
Yamaguchi T; Kohyama N; Takenaka M; Okada T; Kurihara T; Sakurai K; Miwa Y; Kogo M
Clin Rheumatol; 2021 Jul; 40(7):2657-2663. PubMed ID: 33483918
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
[No Abstract] [Full Text] [Related]
34. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.
Delabaye I; De Keyser F;
Arthritis Res Ther; 2010; 12(3):R121. PubMed ID: 20569501
[TBL] [Abstract][Full Text] [Related]
35. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
[TBL] [Abstract][Full Text] [Related]
36. Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity.
Lee JS; Oh JS; Hong S; Kim YG; Lee CK; Yoo B
Int J Rheum Dis; 2020 Aug; 23(8):1076-1081. PubMed ID: 33021334
[TBL] [Abstract][Full Text] [Related]
37. Non-adherence to methotrexate was associated with high disease activity and poor health-related outcomes during a 4-year follow-up of rheumatoid arthritis patients.
Kang JH; Choi SE; Xu H; Park DJ; Lee JK; Lee SS
Clin Exp Rheumatol; 2022 Sep; 40(9):1744-1753. PubMed ID: 35200117
[TBL] [Abstract][Full Text] [Related]
38. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
Gilani ST; Khan DA; Khan FA; Ahmed M
J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.
Bluett J; Sergeant JC; MacGregor AJ; Chipping JR; Marshall T; Symmons DPM; Verstappen SMM
Arthritis Res Ther; 2018 Mar; 20(1):50. PubMed ID: 29554956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
